NICE
NICE turns down Roche’s Ocrevus in early primary progressive multiple sclerosis
June 29, 2018Medical Communications, Sales and Marketing NICE, Ocrevus, Roche, pharma
Roche’s sometimes strained relationship with NICE continues as the health watchdog for England and Wales chose to reject the former’s …
Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori
June 28, 2018Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma
UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …
NICE backs Sanofi’s new treatment for atopic dermatitis
June 22, 2018Medical Communications, Sales and Marketing England, NICE, Sanofi, UK, atopic dermatitis, pharma
NICE has published a positive Final Appraisal Determination FAD recommending dupilumab, in combination with topical corticosteroids, for use on the …
Roche’s Ocrevus cleared for NHS use in relapsing-remitting MS
June 22, 2018Medical Communications, Sales and Marketing MS, NICE, UK, multiple sclerosis, pharma
Roche and multiple sclerosis (MS) patients across England and Wales are celebrating the news that healthcare watchdog NICE has recommended …
NICE turns down Roche’s Perjeta for post-surgery HER2-positive breast cancer
June 15, 2018Medical Communications, Sales and Marketing Cancer, NICE, Perjeta, Roche, breast cancer, pharma
Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the …
NICE recommends MSD’s Keytruda for advanced PD-L1-positive lung cancer
June 5, 2018Research and Development MSD, Merck, NHS, NICE, keytruda, pharma
UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS …
Janssen’s Tremfya gets go-ahead from NICE in plaque psoriasis
May 11, 2018Medical Communications, Sales and Marketing Janssen, NICE, Tremfya, UK, pharma, psoriasis
NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …
UK Ministers call on Vertex to speed up price negotiations
April 23, 2018Sales and Marketing NHS, NICE, Orkambi, UK government, Vertex, biotech, drugs, pharma, pharmaceutical
After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …
Tecentriq third time lucky after NICE nod in lung cancer
April 9, 2018Sales and Marketing NICE, Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq
After having been knocked by twice by NICE, Roche has finally received a recommendation for Tecentriq’s second-line use in non-small …
NICE rejects Dupixent for atopic dermatitis on cost grounds, Sanofi responds
April 4, 2018Research and Development, Sales and Marketing Dupixent, NICE, Sanofi, atopic dermatitis, eczema, pharma
UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of …
NICE turns down Dompe’s eye drops for rare eye condition over price concerns
March 21, 2018Manufacturing and Production, Research and Development, Sales and Marketing Dompe, NICE, cenegermin, neurotrophic keratitis, pharma, rare disease
NICE has announced that it has recommended against the use of Dompe’s recombinant human nerve growth factor eye drop therapy …
NICE recommends Keytruda via CDF as first and only urothelial carcinoma immunotherapy
March 16, 2018Medical Communications, Sales and Marketing MSD, NICE, immunotherapy, keytruda, pharma
UK drugs watchdog NICE has published its finance guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS through …
NICE rejects Eisai’s Halaven in earlier setting for metastatic breast cancer
February 22, 2018Sales and Marketing Brest cancer, Cancer, Eisai, Halaven, NICE, pharma
NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast …
NICE recommends thyroid cancer drug trio for NHS use
February 20, 2018Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer
NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …
NICE backtracks to recommend Roche’s Gazyvaro in follicular lymphoma
February 12, 2018Sales and Marketing Gazyvaro, NHS, NICE, Roche, follicular lymphoma
Roche has announced that NICE has issued its final decision to recommend the use of its Gazyvaro (obinutuzumab). The glyco-engineered …
Latest content
FibroFind appoints Lee Borthwick as CEO
